IceCure Medical Statistics
Total Valuation
IceCure Medical has a market cap or net worth of $79.76 million. The enterprise value is $69.58 million.
Important Dates
The next estimated earnings date is Wednesday, April 2, 2025, before market open.
| Earnings Date | Apr 2, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
IceCure Medical has 56.57 million shares outstanding. The number of shares has increased by 10.71% in one year.
| Current Share Class | 56.57M |
| Shares Outstanding | 56.57M |
| Shares Change (YoY) | +10.71% |
| Shares Change (QoQ) | +5.79% |
| Owned by Insiders (%) | 48.54% |
| Owned by Institutions (%) | 0.30% |
| Float | 29.11M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 18.55 |
| Forward PS | 16.56 |
| PB Ratio | 7.68 |
| P/TBV Ratio | 7.93 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 18.95 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.67, with a Debt / Equity ratio of 0.05.
| Current Ratio | 2.67 |
| Quick Ratio | 2.16 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -111.35% and return on invested capital (ROIC) is -70.31%.
| Return on Equity (ROE) | -111.35% |
| Return on Assets (ROA) | -52.54% |
| Return on Invested Capital (ROIC) | -70.31% |
| Return on Capital Employed (ROCE) | -141.86% |
| Revenue Per Employee | $47,675 |
| Profits Per Employee | -$179,662 |
| Employee Count | 77 |
| Asset Turnover | 0.21 |
| Inventory Turnover | 0.89 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +6.02% in the last 52 weeks. The beta is 2.58, so IceCure Medical's price volatility has been higher than the market average.
| Beta (5Y) | 2.58 |
| 52-Week Price Change | +6.02% |
| 50-Day Moving Average | 1.22 |
| 200-Day Moving Average | 0.86 |
| Relative Strength Index (RSI) | 60.09 |
| Average Volume (20 Days) | 379,181 |
Short Selling Information
The latest short interest is 802,795, so 1.42% of the outstanding shares have been sold short.
| Short Interest | 802,795 |
| Short Previous Month | 883,882 |
| Short % of Shares Out | 1.42% |
| Short % of Float | 2.76% |
| Short Ratio (days to cover) | 2.10 |
Income Statement
In the last 12 months, IceCure Medical had revenue of $3.67 million and -$13.83 million in losses. Loss per share was -$0.29.
| Revenue | 3.67M |
| Gross Profit | 1.60M |
| Operating Income | -14.59M |
| Pretax Income | -14.49M |
| Net Income | -13.83M |
| EBITDA | -14.25M |
| EBIT | -14.59M |
| Loss Per Share | -$0.29 |
Full Income StatementBalance Sheet
The company has $10.67 million in cash and $486,000 in debt, giving a net cash position of $10.19 million or $0.18 per share.
| Cash & Cash Equivalents | 10.67M |
| Total Debt | 486,000 |
| Net Cash | 10.19M |
| Net Cash Per Share | $0.18 |
| Equity (Book Value) | 10.06M |
| Book Value Per Share | 0.18 |
| Working Capital | 8.34M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$10.64 million and capital expenditures -$147,000, giving a free cash flow of -$10.79 million.
| Operating Cash Flow | -10.64M |
| Capital Expenditures | -147,000 |
| Free Cash Flow | -10.79M |
| FCF Per Share | -$0.19 |
Full Cash Flow StatementMargins
| Gross Margin | 43.67% |
| Operating Margin | -397.33% |
| Pretax Margin | -376.85% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
IceCure Medical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.71% |
| Shareholder Yield | -10.71% |
| Earnings Yield | -17.34% |
| FCF Yield | -13.53% |
Analyst Forecast
The average price target for IceCure Medical is $2.70, which is 91.49% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $2.70 |
| Price Target Difference | 91.49% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 81.79% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
IceCure Medical has an Altman Z-Score of -6.29 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.29 |
| Piotroski F-Score | 3 |